Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies

被引:14
作者
Allegra, Alessandro [1 ]
Innao, Vanessa [1 ]
Allegra, Andrea Gaetano [1 ]
Leanza, Rossana [1 ]
Musolino, Caterina [1 ]
机构
[1] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Div Hematol, Messina, Italy
关键词
Exportin; 1; Karyopherins; Leukemia; Multiple myeloma; Selinexor; ACUTE MYELOID-LEUKEMIA; TOPOISOMERASE-II-ALPHA; B-CELL LYMPHOMA; WILD-TYPE P53; BCR-ABL; CYTOPLASMIC LOCALIZATION; SUBCELLULAR-LOCALIZATION; RECURRENT MUTATIONS; XPO1; INHIBITION; CRM1; INHIBITOR;
D O I
10.1016/j.clml.2019.08.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The correct localization of molecules between nucleus and cytoplasm is fundamental for cellular homeostasis and is controlled by a bidirectional transport system. Exportin 1 (XPO1) regulates the passage of numerous cancer-related proteins. In this review, we summarize the development of a novel class of antitumor agents, known as selective inhibitors of nuclear export (SINEs). We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
引用
收藏
页码:E689 / E698
页数:10
相关论文
共 131 条
[1]   Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab [J].
Akyurek, Nalan ;
Uner, Aysegul ;
Benekli, Mustafa ;
Barista, Ibrahim .
CANCER, 2012, 118 (17) :4173-4183
[2]   Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [J].
Alexander, Thomas B. ;
Lacayo, Norman J. ;
Choi, John K. ;
Ribeiro, Raul C. ;
Pui, Ching-Hon ;
Rubnitz, Jeffrey E. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) :4094-+
[3]   Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells [J].
Allegra, Alessandro ;
Innao, Vanessa ;
Gerace, Demetrio ;
Vaddinelli, Doriana ;
Musolino, Caterina .
BLOOD CELLS MOLECULES AND DISEASES, 2016, 62 :49-63
[4]   Vaccination of multiple myeloma: Current strategies and future prospects [J].
Allegra, Alessandro ;
Penna, Giuseppa ;
Innao, Vanessa ;
Greve, Bruna ;
Maisano, Valerio ;
Russo, Sabina ;
Musolino, Caterina .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (02) :339-354
[5]   New orally active proteasome inhibitors in multiple myeloma [J].
Allegra, Alessandro ;
Alonci, Andrea ;
Gerace, Demetrio ;
Russo, Sabina ;
Innao, Vanessa ;
Calabro, Laura ;
Musolino, Caterina .
LEUKEMIA RESEARCH, 2014, 38 (01) :1-9
[6]   Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma [J].
Allegra, Alessandro ;
Penna, Giuseppa ;
Alonci, Andrea ;
Russo, Sabina ;
Greve, Bruna ;
Innao, Vanessa ;
Minardi, Viviana ;
Musolino, Caterina .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) :441-468
[7]   Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors [J].
Allegra, Alessandro ;
Sant'Antonio, Emanuela ;
Penna, Giuseppa ;
Alonci, Andrea ;
D'Angelo, Arianna ;
Russo, Sabina ;
Cannavo, Antonino ;
Gerace, Demetrio ;
Musolino, Caterina .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (02) :93-110
[8]   BCR-ABL nuclear entrapment kills human CMIL cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B [J].
Aloisi, A ;
Di Gregorio, S ;
Stagno, F ;
Guglielmo, P ;
Mannino, F ;
Sormani, MP ;
Bruzzi, P ;
Gambacorti-Passerini, C ;
Saglio, G ;
Venuta, S ;
Giustolisi, R ;
Messina, A ;
Vigneri, P .
BLOOD, 2006, 107 (04) :1591-1598
[9]  
[Anonymous], 2017, BLOOD S1
[10]  
[Anonymous], 2017, BLOOD S1